BACKGROUND AND OBJECTIVES: A group of five Canadian physicians with significant experience in HIV management was convened. Their goal was to develop guidance specifically for Canadian HIV-treating physicians on the appropriate use of etravirine (TMC125, Intelence, Tibotec BVBA, Belgium) in adult HIV-infected patients. METHODS: Evidence from the published literature, conference presentations and expert opinions of the group members were used to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, and from seven other physicians across Canada with clinical HIV treatment expertise and experience in the use of etravirine, as well as two Canadian scientists with HIV expertise. The final recommendations represent the core group's consensus agreement, taking all feedback into consideration. RESULTS AND CONCLUSIONS: The recommendations were developed to guide physicians in the optimal use of etravirine. The issues considered included HIV disease status, antiretroviral treatment history, drug resistance profiles, predictors of response to etravirine, background antiretroviral regimen and drug-drug interactions.
BACKGROUND AND OBJECTIVES: A group of five Canadian physicians with significant experience in HIV management was convened. Their goal was to develop guidance specifically for Canadian HIV-treating physicians on the appropriate use of etravirine (TMC125, Intelence, Tibotec BVBA, Belgium) in adult HIV-infectedpatients. METHODS: Evidence from the published literature, conference presentations and expert opinions of the group members were used to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, and from seven other physicians across Canada with clinical HIV treatment expertise and experience in the use of etravirine, as well as two Canadian scientists with HIV expertise. The final recommendations represent the core group's consensus agreement, taking all feedback into consideration. RESULTS AND CONCLUSIONS: The recommendations were developed to guide physicians in the optimal use of etravirine. The issues considered included HIV disease status, antiretroviral treatment history, drug resistance profiles, predictors of response to etravirine, background antiretroviral regimen and drug-drug interactions.
Authors: Monika Schöller-Gyüre; Wim van den Brink; Thomas N Kakuda; Brian Woodfall; Goedele De Smedt; Hilde Vanaken; Tanja Stevens; Monika Peeters; Kati Vandermeulen; Richard M W Hoetelmans Journal: J Clin Pharmacol Date: 2008-01-14 Impact factor: 3.126
Authors: Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Huldrych F Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman Journal: Top HIV Med Date: 2007 Aug-Sep
Authors: Charles B Hicks; Pedro Cahn; David A Cooper; Sharon L Walmsley; Christine Katlama; Bonaventura Clotet; Adriano Lazzarin; Margaret A Johnson; Dietmar Neubacher; Douglas Mayers; Hernan Valdez Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Koen Andries; Hilde Azijn; Theo Thielemans; Donald Ludovici; Michael Kukla; Jan Heeres; Paul Janssen; Bart De Corte; Johan Vingerhoets; Rudi Pauwels; Marie-Pierre de Béthune Journal: Antimicrob Agents Chemother Date: 2004-12 Impact factor: 5.191
Authors: Kalyan Das; Arthur D Clark; Paul J Lewi; Jan Heeres; Marc R De Jonge; Lucien M H Koymans; H Maarten Vinkers; Frederik Daeyaert; Donald W Ludovici; Michael J Kukla; Bart De Corte; Robert W Kavash; Chih Y Ho; Hong Ye; Mark A Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre De Béthune; Paul L Boyer; Patrick Clark; Stephen H Hughes; Paul A J Janssen; Eddy Arnold Journal: J Med Chem Date: 2004-05-06 Impact factor: 7.446
Authors: Jeffrey P Nadler; Daniel S Berger; Gary Blick; Paul J Cimoch; Calvin J Cohen; Richard N Greenberg; Charles B Hicks; Richard M W Hoetelmans; Kathy J Iveson; Dushyantha S Jayaweera; Anthony M Mills; Monika P Peeters; Peter J Ruane; Peter Shalit; Shannon R Schrader; Stephen M Smith; Corklin R Steinhart; Melanie Thompson; Johan H Vingerhoets; Ellen Voorspoels; Douglas Ward; Brian Woodfall Journal: AIDS Date: 2007-03-30 Impact factor: 4.177
Authors: Anna Figueiredo; Katie L Moore; Johnson Mak; Nicolas Sluis-Cremer; Marie-Pierre de Bethune; Gilda Tachedjian Journal: PLoS Pathog Date: 2006-11 Impact factor: 6.823